Intelligence Feed event · Equity · 2026-07-13

    Eli Lilly Raises 2026 Guidance to $82-85B on Mounjaro/Zepbound Growth

    Question

    Eli Lilly Raises 2026 Guidance to $82-85B on Mounjaro/Zepbound Growth

    Direct answer

    The guidance hike to $82-85B cements Eli Lilly's position as the dominant player in the metabolic health space. The primary constraint remains supply rather than demand, as evidenced by the rapid uptake of Zepbound. Investors are now looking at the sustainability of these growth rates as competitors enter the market in late 2026.

    Original publisher
    Market Ontology
    Evidence through
    2026-07-13
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Eli Lilly Raises 2026 Guidance to $82-85B on Mounjaro/Zepbound Growth”, revision 1, evidence through 2026-07-13. https://marketontology.com/market-events/2026-07-13/eli-lilly-raises-2026-guidance-to-82-85b-on-mounjaro-zepbound-growth-220074

    EQUITY
    Eli Lilly Raises 2026 Guidance to $82-85B on Mounjaro/Zepbound Growth
    The guidance hike to $82-85B cements Eli Lilly's position as the dominant player in the metabolic health space. The primary constraint remains supply rather than demand, as evidenced by the rapid uptake of Zepbound. Investors are now looking at the sustainability of these growth rates as competitors enter the market in late 2026.
    LLY
    Impact
    70
    JUL 13
    SIG
    95%
    LLY
    Eli Lilly Raises 2026 Guidance to $82-85B on Mounjaro/Zepbound Growth
    The guidance hike to $82-85B cements Eli Lilly's position as the dominant player in the metabolic health space. The primary constraint remains supply rather than demand, as evidenced by the rapid uptake of Zepbound. Investors are now looking at the sustainability of these growth rates as competitors enter the market in late 2026.
    → Earnings-driven valuation expansion via upward revision of long-term cash flow projections in the GLP-1 category.
    Impact
    The guidance hike to $82-85B cements Eli Lilly's position as the dominant player in the metabolic health space. The primary constraint remains supply rather than demand, as evidenced by the rapid uptake of Zepbound. Investors are now looking at the sustainability of these growth rates as competitors enter the market in late 2026.
    Affected
    LLY
    Transmission
    Earnings-driven valuation expansion via upward revision of long-term cash flow projections in the GLP-1 category.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month